Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma

Young, Russell; Cailleau, Relda; Mackay, Bruce; Reeves, William J.

doi:10.1007/bf02616069

Cited by 82 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells. Human breast carcinomas (BT-20, MCF-7, and MDA-MB-157) were obtained from the Breast Cancer Task Force, National Cancer Institute (9)(10)(11). Other human nonmammary tumor cells used were obtained from staff at Roswell Park Memorial Institute.…”

Section: Methodsmentioning

confidence: 99%

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Capone¹,

Papsidero²,

Croghan³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Two distinct monoclonal antibodies (mAbs) were effective in the therapy of breast carcinomas of human origin established and growing in nude mice. Passive administration of either of the antibodies produced very rapid (less than 1 week) and significant reduction of in vivo tumor volume. Each of the mAbs showed in vivo targeting of the tumors. Histological analysis of mAb-treated tumors revealed extensive cellular necrosis. Each of the antibodies in vitro was effective in complement-mediated cytolysis at a concentration <1 ng/ml. The tumoricidal responses show that this is a useful model for passive human immunotherapy using mAbs.The treatment of malignant tumors with heteroantisera has been investigated for many years with interesting but inconclusive results (1). Hybridoma technology has provided monoclonal antibody (mAb) reagents, which may circumvent difficulties associated with the use of heteroantisera (2). Tumor-associated mAbs have been developed in the last few years by many workers, and some have investigated therapeutic efficacy in both animal and human subjects (3-5). Investigators have reported on the ability of mAbs to inhibit tumor growth by the administration of a mAb concurrent with or within several days of the implantation of tumor cells (6,7). However, passive mAb therapy has not been reported to decrease the volume of well established progressively growing solid tumors.Recently, mAbs developed in this laboratory against breast cancer cells have been shown to bind the target cells with high specificity (8). Passive immunotherapy experiments were performed to assess the therapeutic potential of these reagents. MATERIALS AND METHODSAnimals. Four-to six-week-old female Swiss nude (nu/nu) athymic mice were obtained from Sprague-Dawley. The mice were maintained in a laminar-flow apparatus under pathogenlimited conditions. Cells. Human breast carcinomas (BT-20, MCF-7, and MDA-MB-157) were obtained from the Breast Cancer Task Force, National Cancer Institute (9-11). Other human nonmammary tumor cells used were obtained from staff at Roswell Park Memorial Institute. MOLT 4 (T-cell leukemia), (B-cell leukemia), Peer (T-cell leukemia), and U-937 (erythroleukemia) were obtained from J. Minowada; K-562 (monocytoid leukemia), from J. Pauly; Chago (lung carcinoma), from B. Schepart; Daudi (Burkitt's lymphoma) and Palarmo (melanoma), from S. Leong and J. Horoszewicz; and AsPC-1 (pancreas carcinoma), from M. Tan. CCRF/SB (B-cell leukemia) and CCRF/ CEM (T-cell leukemia) were obtained from the American Type Culture Collection.All cell lines were maintained in vitro in RPMI 1640 medium/10% fetal calf serum supplemented with glutamine/pyruvate/nonessential amino acids/insulin. Cultures were maintained at 370C in humidified 5% C02/95% air.Tumors. Cells were scraped, washed, and resuspended in RPMI 1640 medium. Tumor-cell viability was assessed by trypan blue dye exclusion, and only cell suspensions of >95% viability were used. The nude mice were injected with 5-10 x 106 cells subcutaneously on their dor...

show abstract

Section: Methodsmentioning

confidence: 99%

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Capone¹,

Papsidero²,

Croghan³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Soule et al (1973) described a slow growing cell line which grew initially in a suspension and although it grew attached in later passages it readily detached from the surface. Young et al (1974) have described a cell line derived from a woman with a medullary carcinoma, a tumour which is reputed to grow better in culture than the more common scirrhous type. Subsequently, these workers described 3 further cell lines obtained from pleural effusions from breast cancer patients and considered them to be tumour cells (Cailleau et al, 1974b).…”

Section: Discussionmentioning

confidence: 99%

Tissue culture studies of malignant effusions

Rh¹,

Hughes²

1975

Br J Cancer

View full text Add to dashboard Cite

Summary.-This study reports attempts to culture tumour cells from 51 malignant effusions using standard tissue culture techniques. Cultures proliferating for more than one month were derived from 42 effusions including 24/32 from breast cancer patients and 5/6 from colon carcinomata. The morphology of these cells and their culture characteristics were compared with that of cells derived from a benign effusion. A common cell type-believed to be of mesothelial origin-was found in all cultures. In addition, fibroblastic cells were common and smaller pleomorphic cells, possibly tumour cells, were found in many effusions. The mesothelial cells were often multinucleated and grew for long periods. Although the tumour cells grew in conjunction with the mesothelial cells, all attempts at separation have failed.These studies indicate that cells derived from malignant effusions may be largely of mesothelial origin although tumour cells may also be present. The use of shortterm cultures of malignant effusions as the source of cells for use as target cells in cytotoxicity tests and in chemotherapy assays is discussed.

show abstract

“…MDA-MB-157 is a human breast cancer cell line negative for expression of HLA class I molecules (17). The MDA-MB-157-HHD clone is a HHD transfectant of MDA-MB-157 cells.…”

Section: Methodsmentioning

confidence: 99%

Characterization of novel breast carcinoma–associated BA46-derived peptides in HLA-A2.1/Db-β2mtransgenic mice

Carmon¹,

Bobilev-Priel²,

Brenner³

et al. 2002

J. Clin. Invest.

View full text Add to dashboard Cite

The human milk fat globule membrane protein BA46 (lactadherin) is highly overexpressed in human breast tumors, making it a potential target for tumor immunotherapy. We have identified BA46-derived peptides that contain the motif recognized by the MHC class I molecule HLA-A2.1 and that are processed and presented by human breast carcinoma cells. In mice lacking normal class I molecules but expressing an HLA-A2.1/Db-β2 microglobulin single chain (HHD mice), three peptides elicited specific CTL activity. Two of these peptides also stimulated cytotoxic activity in peripheral blood lymphocytes from HLA-A2.1–positive breast carcinoma patients. Adoptive transfer of HHD-derived bulk CTLs to nude mice bearing human breast carcinoma transplants reduced tumor growth. These peptides therefore represent naturally processed BA46-derived CTL epitopes that can be used in peptide-based antitumor vaccines

show abstract

Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma

Cited by 82 publications

References 9 publications

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Tissue culture studies of malignant effusions

Characterization of novel breast carcinoma–associated BA46-derived peptides in HLA-A2.1/Db-β2mtransgenic mice

Contact Info

Product

Resources

About